Z. Richardson
4 Papers
Z. Richardson is an academic researcher. The author has contributed to research in topics: Dosing & Medicine. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Stable nebulization and muco‐trapping properties of regdanvimab/IN‐006 support its development as a potent, dose‐saving inhaled therapy for COVID‐19
Morgan D. McSweeney,Ian Stewart,Z. Richardson,Hyun Ah Kang,Yoon A Park,Cheolmin Kim,Karthik Tiruthani,Whitney E. Wolf,Alison Schaefer,Priya A. Kumar,Harendra Aurora,Jeff T. Hutchins,Jong-Moon Cho,Anthony J. Hickey,Soo Young Lee,Samuel Lai +15 more
TL;DR: It is shown that regdanvimab, a potent neutralizing mAb already approved for COVID-19 in several countries around the world, can effectively trap Sars-CoV-2 virus-like-particles in fresh human airway mucus and substantiate nebulized delivery of human antiviral mAbs as a new paradigm in treating SARS-Cov-2 and other respiratory pathologies.
15
Inhaled "Muco-Trapping" Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections.
Morgan D. McSweeney,Sarhad Alnajjar,Alison Schaefer,Z. Richardson,Whitney Wolf,Ian Stewart,Pun Sriboonyapirat,Justin D. McCallen,Ellen Farmer,Bernadette Nzati,Sam Lord,Brian Farrer,Thomas R Moench,Priya A Kumar,Harendra Arora,Raymond J Pickles,Anthony J Hickey,Mark Ackermann,Samuel K Lai +18 more
TL;DR: Inhalable "muco-trapping" variant of motavizumab, a potent neutralizing mAb against RSV F is engineered, and Mota-MT-treated lambs exhibited reduced bronchiolitis, neutrophil infiltration, and airway remodeling than lambs receiving placebo or intramuscular palivizumab.
5
A randomized, double-blind, Phase 1 study of IN-006, an inhaled antibody treatment for COVID-19
Thomas R. Moench,Lauren M Botta,Brian T. Farrer,Jason D. Lickliter,H. Kang,C. Kim,Matthias Hoke,Miles B. Brennan,Morgan D. McSweeney,Z. Richardson,J. Whelan,J. Cho,S. Y. Lee,F. Faurot,Jeff T. Hutchins,Shubin Lai +15 more
TL;DR: In inhaled delivery of a muco-trapping monoclonal antibody for nebulized delivery by a handheld nebulizer, IN-006 was well-tolerated and achieved concentrations in the respiratory tract orders of magnitude above its inhibitory concentration.
5
A randomized, double-blind, Phase 1, single- and multiple-dose placebo-controlled study of the safety and pharmacokinetics of IN-006, an inhaled antibody treatment for COVID-19 in healthy volunteers.
Thomas R. Moench,Lakshmi Botta,Brian Farrer,Jason D. Lickliter,Hyunah Kang,Yoona Park,Cheolmin Kim,Marshall Hoke,Miles Brennan,Morgan D. McSweeney,Z. Richardson,John B. Whelan,F. Faurot,Jeff T Hutchins,Samuel K. Lai +14 more